相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Machine learning for prediction of cutaneous adverse events in patients receiving antiePD-1 immunotherapy
Ryan T. Lewinson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
Aine O'Reilly et al.
SUPPORTIVE CARE IN CANCER (2020)
Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients
Charlee Nardin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Trends in clinical development for PD-1/PD-L1 inhibitors
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Kazushige Yoshida et al.
BMC CANCER (2020)
Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients
L. Bottlaender et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series.
Anna Claire Olsson-Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
Lara Gibellini et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille et al.
JAMA ONCOLOGY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy
A. L. Marano et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors
Hajir Ibraheim et al.
RHEUMATOLOGY (2019)
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Emily Coleman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies
Emily D. Nguyen et al.
DERMATOPATHOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Jacob Siegel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
Michael T. Tetzlaff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis
Ahmad Tarhini et al.
IMMUNOTHERAPY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma
Z. J. Wolner et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Stevens-Johnson syndrome during nivolumab treatment of NSCLC
M. Salati et al.
ANNALS OF ONCOLOGY (2018)
Dermatologic Reactions to Novel Immune Checkpoint Inhibitors
Matthew Ebia et al.
CURRENT DERMATOLOGY REPORTS (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
Yasuhiro Nakamura et al.
JOURNAL OF DERMATOLOGY (2017)
Anti-PD1-induced psoriasis: a study of 21 patients
J. Bonigen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients
Stephanie Saw et al.
EUROPEAN JOURNAL OF CANCER (2017)
Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
Karina L. Vivar et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Management of the cutaneous adverse effects of antimelanoma therapy
Rose Congwei Liu et al.
MELANOMA MANAGEMENT (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
A. Zarbo et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Reinhard Dummer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma
Mark C. Mochel et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma
Namrata Nayar et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Shelley Ji Eun Hwang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Jarushka Naidoo et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
E. Liniker et al.
ONCOIMMUNOLOGY (2016)
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
Rachel L. Kyllo et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Ipilimumab-associated Sweet syndrome in a melanoma patient
Rachel Gormley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
Ross B. Reule et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens et al.
PLOS ONE (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent
SH Jaber et al.
ARCHIVES OF DERMATOLOGY (2006)
分享论文
